Recommendations for raloxifene use in daily clinical practice in the Swiss setting

Abstract

Postmenopausal women between 50 and 70 years of age without climacteric symptoms with either osteopenia or osteoporosis should be evaluated with regard to their breast cancer risk and considered for treatment with raloxifene within the framework of its contraindications and precautions.

Safety of bazedoxifene in Korean women with post-menopausal osteoporosis: a post-marketing surveillance study (PMSS)

“…Patients with renal or hepatic impairment are advised to use the drug with caution, although dose adjustment for patients with mild to moderate renal impairment is not necessary. As with other SERMs, bazedoxifene is known to increase the risk of intravenous thrombosis, and the risk is suggested to be the highest within the first month of initiation of treatment [11]. The most common adverse events reported in clinical studies are hot flushes and leg cramps.…”

The Clinical Choice between Estrogen and Bisphosphonates to Prevent Bone Loss: Are Women Being Misled?

“…In this context, transdermal estradiol is not associated with increased risks of venous thrombosis. Due to the reported stroke in the RUTH study, the recommendation also includes an assessment of the risk for developing stroke before prescribing raloxifene [15,16].…”

The Michel Benoist and Robert Mulholland yearly European Spine Journal Review

“…Lippuner et al [21] have published an excellent article in the December issue on the use of raloxifene in osteoporosis. Raloxifene is a selective estrogen receptor modulator (SERM).…”